The Paris Junket: Why 30 Doctors Are Under Scrutiny for Pharma-Funded Trips

Despite clear evidence of ethics violations, state medical councils have yet to penalise doctors caught accepting a Rs 2 crore foreign trip sponsored by AbbVie.

The promise of a medical conference in Paris or a luxury stay in Monaco is a far cry from the cramped OPDs where most patients encounter their doctors. Yet, investigations have revealed that 30 doctors across nine states allegedly traded their professional independence for these high-end, pharma-funded junkets. While the National Medical Commission (NMC) has flagged these individuals as guilty of violating ethical guidelines, the wheels of accountability are turning at a glacial pace, stalled by a lack of response from state-level bodies.

The trail of the controversy leads back to a massive Rs 2 crore bill footed by the pharmaceutical giant AbbVie. RTI filings have exposed that the Department of Pharmaceuticals narrowed down a list of 30 doctors, yet only 27 names were forwarded to the NMC. The mystery of the three missing names remains unexplained, leaving a gap in the accountability chain that critics argue compromises the entire investigation.

A Trail of Indifference

The breach of protocol is widespread, spanning Maharashtra, Gujarat, Telangana, Punjab, Karnataka, West Bengal, Delhi, Assam, and Kerala. Maharashtra alone accounts for 11 of the flagged doctors, highlighting a concentrated pattern of influence. When the NMC dispatched these names to the respective State Medical Councils (SMCs) on December 15, 2025, the directive was explicit: conduct an enquiry and impose necessary penalties.

Six months on, the silence from six of these states is deafening. The NMC’s ethics board, clearly frustrated, issued a stern reminder on May 26, 2025, demanding that Assam, Delhi, Karnataka, Kerala, Telangana, and West Bengal finally act. For now, the doctors remain in practice, and the pharma firm behind the largesse faces no public disciplinary action, raising questions about the efficacy of current oversight mechanisms.

The Bigger Picture

This incident is not merely about a few free trips; it is a symptom of a systemic "nexus" between industry and medicine that continues to erode public trust. When medical decisions are perceived to be influenced by luxury incentives rather than clinical efficacy, the entire healthcare ecosystem suffers. The fact that state councils—which are the first line of defense in maintaining professional ethics—are dragging their feet suggests either a lack of administrative urgency or a reluctance to take on influential members of the medical fraternity.

The delay effectively signals to the industry that such practices carry little risk. Unless these councils move beyond administrative correspondence and actually deliver punitive measures, the NMC’s directives will remain toothless. The integrity of the profession depends on the state bodies proving that no practitioner is above the code of ethics, regardless of their reach or the deep pockets of the pharma firms involved.